P. Brennan

发表

The Role of Protein Structural Analysis in the Next Generation Sequencing Era

W. Yue, D. S. Froese, P. Brennan, 2012, Topics in current chemistry.

A genetics-led approach defines the drug target landscape of 30 immune-related traits

Hinrich W. H. Göhlmann, David R. Damerell, J. Knight, 2019, Nature Genetics.

Targeting the Small GTPase Superfamily through Their Regulatory Proteins

P. Brennan, F. Delft, J. Gray, 2020, Angewandte Chemie.

Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.

S. Knapp, P. Brennan, C. Schofield, 2012, Journal of medicinal chemistry.

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

S. Knapp, O. Fedorov, C. Bountra, 2013, Proceedings of the National Academy of Sciences.

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

S. Knapp, J. Bradner, O. Fedorov, 2013, Cancer research.

The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains.

S. Knapp, O. Fedorov, P. Brennan, 2013, MedChemComm.

Chemical Epigenetics

L. Altucci, A. Mai, P. Brennan, 2020 .

Exploring the role of water in molecular recognition: predicting protein ligandability using a combinatorial search of surface hydration sites

P. Brennan, D. Huggins, S. Vuković, 2016, Journal of physics. Condensed matter : an Institute of Physics journal.

Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.

R. Klose, F. von Delft, P. Ratcliffe, 2012, Journal of medicinal chemistry.

Bench-Stable Transfer Reagent Facilitates the Generation of Trifluoromethyl-sulfonimidamides.

P. Brennan, Daniel Oehlrich, M. Wright, 2018, The Journal of organic chemistry.

LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor**

S. Knapp, O. Fedorov, S. Müller, 2015, Angewandte Chemie.

A chemical toolbox for the study of bromodomains and epigenetic signaling

Shili Duan, Mathieu Lupien, Stefan Knapp, 2018, bioRxiv.

Target Identification Using Chemical Probes.

P. Brennan, F. McCann, G. Farnie, 2018, Methods in enzymology.

Identifying Small‐Molecule Binding Sites for Epigenetic Proteins at Domain–Domain Interfaces

S. Knapp, F. von Delft, P. Brennan, 2018, ChemMedChem.

Development of chemical probes for the bromodomains of BRD7 and BRD9.

P. Brennan, D. Dixon, P. G. Clark, 2016, Drug discovery today. Technologies.

Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains

S. Knapp, O. Fedorov, S. Müller, 2015 .

Recent Progress in Histone Demethylase Inhibitors.

Akane Kawamura, Christopher J Schofield, Paul E Brennan, 2016, Journal of medicinal chemistry.

A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL) YEATS domain

S. Knapp, O. Fedorov, P. Brennan, 2018, bioRxiv.

Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL).

S. Knapp, O. Fedorov, P. Brennan, 2018, Journal of medicinal chemistry.

5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation.

R. Klose, W. Yue, P. Ratcliffe, 2013, Chemical science.

Deregulation of Chromosome Segregation and Cancer

G. F. Ruda, P. Brennan, V. Bolanos-Garcia, 2020 .

Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening

G. F. Ruda, Yanling Zhang, O. Fedorov, 2018, bioRxiv.

Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance

S. Knapp, P. Biggin, O. Fedorov, 2015, Science Advances.

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors

G. F. Ruda, O. Fedorov, C. Bountra, 2016, Journal of medicinal chemistry.

SuCOS is Better than RMSD for Evaluating Fragment Elaboration and Docking Poses

G. Morris, M. Bodkin, F. von Delft, 2019 .

Chapter 8 Inhibitors of JmjC-containing Histone Demethylases

P. Brennan, A. Kawamura, M. Wright, 2020 .

An Activity‐Based Probe Targeting Non‐Catalytic, Highly Conserved Amino Acid Residues within Bromodomains

M. Schirle, S. Knapp, O. Fedorov, 2018, Angewandte Chemie.

Imaging articular cartilage in osteoarthritis using targeted peptide radiocontrast agents

P. Brennan, F. Cacho-Nerin, P. Das Neves Borges, 2022, PloS one.

Deliberately Losing Control of C−H Activation Processes in the Design of Small‐Molecule‐Fragment Arrays Targeting Peroxisomal Metabolism

J. Spencer, P. Brennan, F. Delft, 2020, ChemMedChem.

A Chemical Probe For Tudor Domain Protein Spin1 to Investigate Chromatin Functions

O. Fedorov, C. Bountra, C. Arrowsmith, 2019 .

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation

D. Brough, G. Tresadern, P. Brennan, 2021, Scientific Reports.

Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening

G. A. Bezerra, F. von Delft, W. Yue, 2022, Frontiers in Chemistry.

Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF

S. Knapp, O. Fedorov, S. Müller, 2015, Journal of medicinal chemistry.

Synthesis and Biological Investigation of (+)-JD1, an Organometallic BET Bromodomain Inhibitor

Hannah J. Maple, T. Chevassut, O. Fedorov, 2019, Organometallics.

Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma

P. Brennan, 2016, Cell Death and Disease.

Discovery of an MLLT1/3 YEATS Domain Chemical Probe

Jennifer A. Ward, S. Knapp, G. Poda, 2018, Angewandte Chemie.

Discovery of a PCAF Bromodomain Chemical Probe

S. Knapp, O. Fedorov, P. Brennan, 2016, Angewandte Chemie.

Structural Insights into Interaction Mechanisms of Alternative Piperazine-urea YEATS Domain Binders in MLLT1.

S. Knapp, O. Fedorov, P. Brennan, 2019, ACS medicinal chemistry letters.

Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1

S. Knapp, O. Fedorov, P. Brennan, 2019, bioRxiv.

Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.

S. Knapp, O. Fedorov, M. Bunnage, 2016, Journal of medicinal chemistry.

Halogen-aromatic π interactions modulate inhibitor residence time

R. Wade, S. Knapp, P. Brennan, 2018, bioRxiv.

Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2

S. Knapp, O. Fedorov, J. Elkins, 2018, Bioorganic & medicinal chemistry.

Halogen-Aromatic π Interactions Modulate Inhibitor Residence Times.

R. Wade, S. Knapp, P. Brennan, 2018, Angewandte Chemie.

Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.

M. Andrews, A. Brown, P. Fish, 2011, Bioorganic & medicinal chemistry letters.

Assessing histone demethylase inhibitors in cells: lessons learned

G. F. Ruda, O. Fedorov, C. Bountra, 2017, Epigenetics & Chromatin.

Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.

S. Knapp, O. Fedorov, S. Müller, 2016, Journal of medicinal chemistry.

A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation–π Interaction**

Stefan Knapp, Robert S Paton, Susanne Müller, 2014, Angewandte Chemie.

A general and mild two-step procedure for the synthesis of aryl and heteroaryl sulfonamides from the corresponding iodides

P. Brennan, L. Chan, D. H. Ho, 2011 .

Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex

Julian E. Fuchs, S. Knapp, J. Brenton, 2016, Journal of medicinal chemistry.

Application of the intramolecular azomethine imine cycloaddition to the construction of a novel, orthogonally protected spirodiamino acid scaffold

P. Brennan, R. Dolle, D. Ho, 1999 .

Total synthesis of rapamycin.

Matthew L. Maddess, S. Marsden, S. Ley, 2009, Chemistry.

A tandem asymmetric synthesis approach for the efficient preparation of enantiomerically pure 9-(hydroxyethyl) anthracene

P. Brennan, Alexis Jaunet, Simon Jones, 2011 .

[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains

S. Knapp, O. Fedorov, S. Müller, 2013, Journal of medicinal chemistry.

Total synthesis of rapamycin.

Matthew L. Maddess, S. Ley, P. Brennan, 2007, Angewandte Chemie.

Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands

S. Knapp, O. Fedorov, P. Brennan, 2013, Journal of medicinal chemistry.

Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.

P. Brennan, G. McMurray, G. Whitlock, 2009, Bioorganic & medicinal chemistry letters.

Palladium-containing perovskites: recoverable and reuseable catalysts for Suzuki couplings.

A. Stepan, S. Ley, P. Brennan, 2003, Chemical communications.

Mild, calcium catalysed Beckmann rearrangements.

P. Brennan, M. McLaughlin, H. Kiely-Collins, 2018, Chemical communications.

Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains

S. Knapp, O. Fedorov, M. Bunnage, 2014, Journal of the American Chemical Society.

Highly selective inhibition of histone demethylases by de novo macrocyclic peptides

T. Katoh, S. Müller, P. Brennan, 2017, Nature Communications.

The promise and peril of chemical probes.

John P. Overington, Jian Jin, Matthieu Schapira, 2015, Nature chemical biology.

Erratum: The promise and peril of chemical probes (Nature Chemical Biology (2015) 11 (536-541))

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac

G. F. Ruda, Lishuang Cao, E. Carpenter, 2015, Science.

Synthesis of meta-substituted arene bioisosteres from [3.1.1]propellane

P. Brennan, C. Schofield, Jeremy Nugent, 2022, Nature.

Fragment-based hit identification: thinking in 3D.

Nathan Brown, Steven V Ley, Kristian Birchall, 2013, Drug discovery today.

Chemical Strategies for Evaluating New Drug Targets

M. Sundström, P. Brennan, Adrian J Carter, 2019, Methods and Principles in Medicinal Chemistry.

TargetDB: A target information aggregation tool and tractability predictor

Stephane P. De Cesco, John B. Davis, Paul E. Brennan, 2020, bioRxiv.

Synthesis of carbohydrate derivatives using solid-phase work-up and scavenging techniques.

S. Ley, P. Brennan, Rachel N. Maccoss, 2003, Organic & biomolecular chemistry.

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death

Richard G. Jenner, A. Cribbs, U. Oppermann, 2020, Cancer Research.

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

A chemical toolbox for the study of bromodomains and epigenetic signaling

S. Knapp, O. Fedorov, M. Lupien, 2018, Nature Communications.

RHO to the DOCK for GDP disembarking: Structural insights into the DOCK GTPase nucleotide exchange factors

F. von Delft, P. Brennan, J. Gray, 2021, The Journal of biological chemistry.

Chemogenomics for drug discovery: clinical molecules from open access chemical probes

Robert B A Quinlan, Paul E Brennan, P. Brennan, 2021, RSC chemical biology.

Chemical probes and inhibitors of bromodomains outside the BET family† †The authors declare no competing interests.

Paul E Brennan, P. Brennan, D. Hay, 2016, MedChemComm.

Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.

S. Knapp, O. Fedorov, S. Müller, 2017, Journal of medicinal chemistry.

The structural basis of fatty acid elongation by the ELOVL elongases

G. F. Ruda, E. Carpenter, P. Brennan, 2020, Nature Structural & Molecular Biology.

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors

A. Degterev, A. Bullock, S. Ray, 2015, Chemistry & biology.

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors

O. Fedorov, F. von Delft, Stephane De Cesco, 2023, Pathogens.

Human Kelch-like protein 20 (KLHL20) A Target Enabling Package (TEP)

O. Fedorov, A. Bullock, P. Brennan, 2020 .

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

S. Knapp, O. Fedorov, P. Wordsworth, 2015, Proceedings of the National Academy of Sciences.

Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells

M. Vedadi, P. Brennan, R. Wade-Martins, 2020, The Journal of Biological Chemistry.

Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).

O. Fedorov, C. Arrowsmith, D. Dilworth, 2019, Journal of medicinal chemistry.

Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators

P. Brennan, K. Huber, Elisabeth M. Rothweiler, 2022, Biological chemistry.

Structural analysis of human KDM5B guides histone demethylase inhibitor development.

R. Prinjha, U. Oppermann, P. Brennan, 2016, Nature chemical biology.

Chemical Probes

W. Zuercher, P. Brennan, A. Donner, 2019, Epigenetic Drug Discovery.

Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib.

Alexander Pautsch, Stefan Knapp, Roman Fischer, 2016, ACS chemical biology.

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Andrew J. Bannister, S. Robson, S. Knapp, 2015, Cancer research.

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

S. Knapp, M. Bunnage, P. Fish, 2012, Journal of medicinal chemistry.

Inhibitors of JmjC-Containing Histone Demethylases

P. Brennan, A. Kawamura, M. Wright, 2019, Topics in Medicinal Chemistry.

Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells

Akane Kawamura, Christopher J. Schofield, Faith Davies, 2017, Cell chemical biology.

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors

O. Fedorov, C. Bountra, A. Cribbs, 2018, Angewandte Chemie.

Advances and challenges in understanding histone demethylase biology.

U. Oppermann, P. Brennan, C. Johansson, 2016, Current opinion in chemical biology.

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis

Shwu‐Yuan Wu, C. Chiang, P. Brennan, 2017, Scientific Reports.

Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia

E. Tunbridge, P. Brennan, Annette von Delft, 2021, CNS Drugs.

BET inhibition as a new strategy for the treatment of gastric cancer

S. Knapp, O. Fedorov, S. Müller, 2016, Oncotarget.

Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain

S. Knapp, G. Siegal, O. Fedorov, 2016, Journal of medicinal chemistry.

Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.

Robert P. DePianta, V. Shanmugasundaram, A. Brown, 2014, Journal of medicinal chemistry.

Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity.

P. Beauchemin, G. F. Ruda, H. Lassmann, 2021, Cell reports.

Epigenetic inactivation of oncogenic brachyury (TBXT) by H3K27 histone demethylase controls chordoma cell survival

A. Cribbs, U. Oppermann, A. Flanagan, 2018, bioRxiv.

Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.

R. Denny, P. Brennan, M. Pletcher, 2017, Journal of medicinal chemistry.

The therapeutic potential of acetyl-lysine and methyl-lysine effector domains

S. Knapp, P. Brennan, P. Filippakopoulos, 2012 .

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays

G. F. Ruda, O. Fedorov, O. Rossanese, 2019, European journal of medicinal chemistry.

Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia

F. von Delft, W. Yue, P. Brennan, 2021, ACS chemical biology.

Target 2035 – update on the quest for a probe for every protein

G. A. Bezerra, T. Willson, G. Superti-Furga, 2021, RSC medicinal chemistry.

Discovery of a Highly Selective Cell‐Active Inhibitor of the Histone Lysine Demethylases KDM2/7

O. Fedorov, S. Müller, Barbara Mair, 2017, Angewandte Chemie.

Betti reaction enables efficient synthesis of 8-hydroxyquinoline inhibitors of 2-oxoglutarate oxygenases.

S. Müller, P. Ratcliffe, P. Brennan, 2015, Chemical communications.

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor†

F. von Delft, P. Brennan, N. Burgess-Brown, 2014, MedChemComm.

Potent and selective alpha1A adrenoceptor partial agonists--novel imidazole frameworks.

P. Brennan, G. Whitlock, A. Stobie, 2009, Bioorganic & medicinal chemistry letters.

Potent and Selective α1A Adrenoceptor Partial Agonists — Novel Imidazole Frameworks.

P. Brennan, G. Whitlock, A. Stobie, 2009 .

Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography

Julien Rossignol, Steven V. Ley, Stefan Knapp, 2014 .

A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc03115j

Frank von Delft, Brian D Marsden, Patrick Collins, 2015, Chemical science.

Palladium‐Containing Perovskites: Recoverable and Reusable Catalysts for Suzuki Couplings.

A. Stepan, S. Ley, P. Brennan, 2004 .

Development of Selective ADAMTS-5 Peptide Substrates to Monitor Proteinase Activity

P. Brennan, M. Meldal, T. Vincent, 2023, Journal of medicinal chemistry.

Human Receptor-Interacting Serine / Threonine-Protein Kinase 2 ( RIPK 2 ) A Target Enabling Package ( TEP )

Jennifer A. Ward, S. Knapp, A. Degterev, 2020 .

Combinatorial synthetic design. Solution and polymer-supported synthesis of heterocycles via intramolecular aza Diels-Alder and imino alcohol cyclizations.

P. Brennan, P. Bartlett, M. Spaller, 2002, Journal of combinatorial chemistry.

Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s disease

A. Levey, S. Frye, K. Pearce, 2023, bioRxiv.

Open drug discovery in Alzheimer's disease

A. Levey, L. Mangravite, A. Axtman, 2023, Alzheimer's & dementia.

Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation

A. Gingras, S. Knapp, O. Fedorov, 2017, ACS chemical biology.

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

A. Gingras, S. Knapp, O. Dovey, 2016, Science Advances.

LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor†

S. Knapp, O. Fedorov, S. Müller, 2015, Angewandte Chemie.

A chemical toolbox for the study of bromodomains and epigenetic signaling

S. Knapp, O. Fedorov, M. Lupien, 2019, Nature Communications.

Assessing histone demethylase inhibitors in cells: lessons learned

G. F. Ruda, O. Fedorov, C. Bountra, 2017, Epigenetics & Chromatin.

Discovery of Novel Azepine Series of Potent and Selective 5‐HT2C Agonists as Potential Treatments for Urinary Incontinence.

P. Brennan, G. McMurray, G. Whitlock, 2010 .

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM

Jessica E. Young, K. Pearce, A. Axtman, 2023, bioRxiv.

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

The X-linked histone demethylases KDM5C and KDM6A as regulators of T cell-driven autoimmunity in the central nervous system

G. F. Ruda, P. Brennan, Mohamed Reda Fazazi, 2023, Brain Research Bulletin.

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.

S. Knapp, O. Fedorov, S. Müller, 2017, Journal of medicinal chemistry.

O. Fedorov, F. von Delft, J. Spencer, 2015, Chemical science.

Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2

O. Gileadi, P. Brennan, J. Benesch, 2023, bioRxiv.

Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.

P. Brennan, Sheng-yong Yang, Luyi Huang, 2019, Journal of medicinal chemistry.

The X-linked histone demethylases KDM5C and KDM6A as regulators of T cell-driven autoimmunity in the central nervous system

G. F. Ruda, P. Brennan, Mohamed Reda Fazazi, 2023, Brain Research Bulletin.

A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.

O. Fedorov, C. Bountra, C. Arrowsmith, 2019, Journal of medicinal chemistry.

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor†

F. von Delft, P. Brennan, N. Burgess-Brown, 2014, MedChemComm.

5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation.

R. Klose, W. Yue, P. Ratcliffe, 2013, Chemical science.

The promise and peril of chemical probes (vol 11, pg 536, 2015)

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.

Andrew J. Bannister, S. Robson, S. Knapp, 2015, Cancer research.

Mild, calcium catalysed Beckmann rearrangements.

P. Brennan, H. Kiely-Collins, I. Sechi, 2018, Chemical communications.